**Core tip:** Few patients can undergo surgery for treatment of non-small-cell lung cancer because of advanced disease or poor pulmonary function. Combination of bronchial artery infusion of anti-cancer agents and oral targeted drug is safe, tolerable, and effective for patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer (NSCLC). Complete remission of advanced NSCLC can be achieved by this combination therapy.

INTRODUCTION
============

Advanced lung cancer is inoperable, and systemic chemotherapy, radiotherapy, or complementary and alternative therapies are usually unsatisfactory. Bronchial artery infusion (BAI) has become an effective treatment for patients with unresectable non-small-cell lung cancer (NSCLC). During this procedure, chemotherapeutic drugs at high concentrations are injected directly into the bronchial arteries which provide blood supply to the tumors, thus the symptoms and adverse effects caused by the anti-cancer drugs are greatly reduced. Treatment with oral targeted drug is very convenient and has been proposed as a novel therapy for patients with advanced NSCLC. As a novel targeted drug and highly specific epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), icotinib hydrochloride (BPI-2009H, ConMana) has been shown to be potent and provide a survival benefit in selected patients with advanced NSCLC\[[@B1]\]. And it has been approved as the first-line therapy in patients with advanced NSCLC with sensitive mutation on February 22, 2011, by China Food and Drug Administration (CFDA)\[[@B2]\]. Oral icotinib combined with BAI chemotherapy can yield a synergetic and complementary effect in patients with advanced NSCLC. We herein describe an elderly patient with advanced NSCLC who was treated with oral icotinib hydrochloride combined with BAI chemotherapy as the first-line therapy, which resulted in a very good clinical outcome.

CASE REPORT
===========

A 73-year-old man, who had never smoked and no relevant medical and family history, was admitted to our institution on February 24, 2014 with a 2-mo history of cough. After a series of medical examinations including laboratory examinations, Transverse computed tomography (CT) scan, percutaneous lung biopsy and genetic testing, he was diagnosed with advanced NSCLC (left lower lobe, peripheral type, pT~4~cN~0~M~0~, stage IIIA adenocarcinoma, moderate differentiation), and EGFR mutation was found with the L858R substitution in exon 21. He was not a candidate for surgical treatment because of his poor lung function and the grade 3 physical performance evaluated by Eastern Cooperative Oncology Group performance score. The patient denied radiotherapy or systemic chemotherapy, but opted for transarterial infusion chemotherapy and oral targeted drugs.

Witten informed consent was obtained from the patient before the BAI. On February 28, 2014 after sufficient preoperative preparation, the patient received left bronchial artery chemical infusion (Figure [1](#F1){ref-type="fig"}) with 60 mg cisplatin, 40 mg hydroxycamptothecine, and 1000 mg 5-fluorouracil, respectively. On March 4, 2014, the patient started to take icotinib hydrochloride orally (125 mg, every eight hours).

![Selective arterial angiography showing notable contrast agent diffusion in the left lower lung, indicating blood supply to the tumor (white arrow).](WJCC-6-150-g001){#F1}

A follow-up CT scan was performed 39 d after the BAI and 34 d after the beginning of oral icotinib hydrochloride. It revealed that the tumor regressed significantly compared with that in the early image (Figure [2A](#F2){ref-type="fig"} and B). No adverse reaction was observed, and the objective response was evaluated to be partial response according to Response Evaluation Criteria in Solid Tumors 1.1 criteria (RECIST 1.1)\[[@B3]\], and the physical conditions and the quality of life of the patient were markedly improved. His physical performance was scored as grade 1.

![Transverse computed tomography scan findings of patients before and during treatment. A: Pre-treatment transverse computed tomography (CT) scan showing the tumor mass in the basal segment of the left lower lobe. The greatest dimension of the tumor measured 5.7 cm; B: One month after treatment, transverse CT scan showed significant reduction in tumor size. The greatest dimension measured 3.5 cm; C: Seven months after treatment, CT scan showed further significant reduction in tumor size. Greatest dimension was reduced to 1.8 cm; D: CT scan 45 mo after treatment showed that tumor almost disappeared (only fiber scar tissue was found by puncture biopsy).](WJCC-6-150-g002){#F2}

Seven months later, another transverse CT scan showed that the tumor further regressed (Figure [2A](#F2){ref-type="fig"} and C), and the objective response was evaluated to be approximately complete regression (CR) as a biopsy of the lesion showed no tumor cells, but fiber scar tissue. His physical performance was scored as grade 1.

Up till now, the patient has taken oral icotinib hydrochloride for more than 48 mo, and the latest transverse CT scan on December 17, 2017 showed that the tumor tissue almost disappeared (Figure [2C](#F2){ref-type="fig"} and D). The objective response was evaluated to be approximately CR, and his physical performance was scored as grade 1.

DISCUSSION
==========

Intra-arterial infusion chemotherapy has been introduced to medical treatment of tumors for more than 50 years\[[@B4]\]. This therapy has the potential to reduce the tumor size and to relieve symptoms, with low toxicity and good repeatability. It is especially suitable for the patients with advanced lung cancer who are intolerable to systemic chemotherapy or radiotherapy\[[@B5]-[@B8]\]. Therefore, it is a treatment option for advanced NSCLC patients.

The feeding arteries of locally advanced lung cancer include not only the bronchial arteries, but also various other feeding arteries, which need to be detected precisely by arterial angiography\[[@B5]\]. Precise and extensive angiographic examinations to detect feeding arteries are crucial, and a prerequisite for achieving positive results. A study reported that, among the feeding arteries of lung cancer, bronchial arteries showed the best response to BAI\[[@B6]\]. This method employs direct injection of chemotherapeutics at high concentrations into local lesions of lung cancer and only needs half of the dosage required for systemic chemotherapy\[[@B9],[@B10]\]. The local potency of the anti-cancer drugs administered *via* BAI to the lesion area is 2-6 times that of the same drugs administered *via* the intra-venous route\[[@B11]\]. Another study reported that the overall effective rate of BAI was 55.3% in patients with stage III hilar lung cancer\[[@B9]\]. One study demonstrated that the BAI therapy not only reduced the tumor size but also extended patient survival, and improved quality of life of the patients\[[@B5]\].

BAI therapy has the following advantages: allowing doctors to utilize small dosage of anti-cancer agents, but deliver relatively large dosage of the agents into the tumor in situ with minimal systemic side effects to achieve high efficiency of local control, and this therapy is safe and feasible because the side effects are mild\[[@B5],[@B8]\].

However, the efficacy of this therapy for lung cancer has not been sufficiently verified, and BAI is an invasive treatment which may lead to some severe adverse effects, such as spinal paralysis, bronchial ulcers, esophageal ulcers, hemoptysis, pulmonary toxicity and renal injury\[[@B12]\]. We used cisplatin, hydroxycamptothecine and 5-fluorouracil as arterial infusion chemotherapy agents. However, it is necessary to determine the appropriate dosages of the chemotherapeutic drugs for selected patients\[[@B5]\]. During this treatment, just like for systemic chemotherapy, the patients need to be hospitalized repeatedly, which consumes more time on taking care of the patients and increases the economic burden of the patients. These limitations prevent the wide application of BAI as a standard clinical therapy for lung cancer\[[@B5],[@B6]\]. Nevertheless, in our case, the patient was hospitalized only once and received only one procedure of BAI to control rapid growth of the tumor, and the total hospitalization expense was 1728.3 US Dollar, which was markedly lower compared to the expenses for other therapeutic methods.

A current single-center retrospective study which enrolled 40 consecutive patients with advanced NSCLC who underwent transcatheter arterial chemical infusion showed that the total response rate was 32.5%, the disease control rate was 92.5%, and the mean time to tumor progression (TTP) and overall survival (OS) was 9.2 ± 1.4 and 13.1 ± 2.0 mo, respectively\[[@B13]\]. However, the long-term outcome and overall survival are still unclear. The beneficial effect of regional therapy on survival or disease control is usually limited when used alone.

NSCLC with mutations in the EGFR gene is a distinct subgroup of NSCLCs which is particularly sensitive to EGFR-TKIs\[[@B14],[@B15]\]. The most common EGFR mutations in NSCLC were the L858R substitution in exon 21 and the deletions in exon 19. EGFR-TKI is the most effective therapy for patients with advanced EGFR-mutant NSCLC\[[@B16]\].

Icotinib hydrochloride is the first self-developed small molecular drug in China, and was approved by the State Food and Drug Administration of China for the treatment of locally advanced or metastatic NSCLC\[[@B1],[@B17]\]. It was demonstrated that icotinib is inferior to gefitinib in terms of median progression free survival (PFS)\[[@B18]\]. A single-center study evaluated the efficacy of icotinib after its approval as a monotherapy for advanced NSCLC patients with EGFR mutation and patients with wild-type EGFR. The results showed that in the 36 patients with EGFR mutation, the overall response rate (ORR) and disease control rate (DCR) were 58.3% and 88.9%, respectively; while in the 13 patients with wild-type EGFR, the ORR and DCR were 7.7% and 53.8%, respectively\[[@B19]\]. Another study evaluated the efficacy of icotinib as the first-line treatment of pulmonary adenocarcinoma and showed that among a total of 56 patients with lung adenocarcinoma, the ORR and DCR were 46.4% (26/56) and 78.6% (46/56), respectively. In the patients with EGFR mutation, the ORR and DCR were 66.7% (12/18) and 94.4% (17/18), respectively\[[@B20]\].

After long-term treatment with oral targeted drugs, however, nearly all the patients will inevitably develop drug resistance with disease progression after 6-12 mo of treatment\[[@B21],[@B22]\]. Therefore, more in-depth studies on optimizing combination strategies and overcoming drug resistance to icotinib are warranted\[[@B22]\]. One study reported that combination of EGFR-TKI therapy and systemic chemotherapy yielded disappointing results after disease progression using the first-line EGFR-TKI therapy\[[@B23]\]. But an ASPIRATION trial (Asian Pacific trial of Tarceva as first-line therapy in EGFR mutation) showed that, when the first disease progression occurred, continuing with EGFR-TKI therapy might be beneficial in patients with asymptomatic and slow progression\[[@B24]\].

Therefore, we propose the use of arterial infusion chemotherapy in combination with EGFR-TKI therapy as the first-line therapy for disease control in patients with EGFR-mutant advanced NSCLC to achieve better therapeutic effects, extend the progression-free survival (PFS) and OS, and improve quality of life of the patients. A study on EGFR-TKI therapy in combination with arterial infusion chemotherapy reported that the median OS was 28.6 mo (range, 24.1-32.9 mo)\[[@B25]\]. In our case, the patient received arterial infusion chemotherapy combined with oral icotinib therapy as the first-line therapy and no apparent adverse effects were observed during the treatment for more than 48 mo. After the first cycle of icotinib (30 d), objective tumor response was evaluated to be partial remission without any adverse effects such as diarrhoea, acneiform skin rash, paronychia, and so on\[[@B26]\], and physical conditions and the quality of life were markedly improved. The objective tumor response was evaluated to be almost CR, and further puncture biopsy will be obtained to confirm the therapeutic results at an appropriate time. The patient remained in good physical condition and the quality of life. Nevertheless, if possible, percutaneous ablation or minimally invasive thoracoscopic surgery may be performed to eliminate the residual fibrous scar tissue for radical cure.

Although BAI chemotherapy has the advantage of short treatment time and mild toxicity, its wide application is limited because of the requirements for sophisticated physician skills and specialized equipment. These two methods have been separately used in the treatment of NSCLC and resulted in relatively positive clinical efficacy. The combination of the two therapies is considered to generate synergetic and complementary effect in advanced NSCLC. However, the clinical efficacy of BAI chemotherapy combined with targeted therapy for the treatment of advanced NSCLC remains to be further investigated, and results from statistical analysis about the benefit of the treatment based on large-scale clinical trials are needed.

This case report suggests that the combination of oral icotinib hydrochloride and BAI chemotherapy is safe, well-tolerated and effective in Chinese patients suffering from advanced NSCLC with EGFR gene mutations. This strategy can be attempted for complete tumor remission.

ARTICLE HIGHLIGHTS
==================

Case characteristics
--------------------

A 73-year-old man who was diagnosed with advanced non-small-cell lung cancer (NSCLC), received the combination therapy of bronchial artery infusion chemotherapy and oral icotinib hydrochloride, and the objective response was evaluated to be approximately complete regression.

Clinical diagnosis
------------------

The patient was admitted to our institution with a 2-mo history of cough.

Differential diagnosis
----------------------

The differential diagnosis included pulmonary tuberculosis, lobular pneunonia, or benign lung tumors.

Laboratory diagnosis
--------------------

Blood test was normal. Genetic testing revealed that epidermal growth factor receptor (EGFR) mutation was found with the L858R substitution in exon 21.

Imaging diagnosis
-----------------

Transverse computed tomography scan showed the tumor mass in the basal segment of the left lower lobe and the greatest dimension of the tumor measured 5.7 cm.

Pathological diagnosis
----------------------

Examination of the pathologic specimen after percutaneous lung biopsy, confirmed a moderate differentiated adenocarcinoma.

Treatment
---------

The patient received left bronchial artery chemical infusion (60 mg cisplatin, 40 mg hydroxycamptothecine, and 1000 mg 5-fluorouracil, respectively) and oral icotinib hydrochloride (125 mg, every eight hours) was initiated on postoperative day 4.

Related reports
---------------

Other studies on EGFR-TKI therapy in combination with arterial infusion chemotherapy reported that the median OS was 28.6 mo, and in our case, the patient received the treatment for more than 48 mo without apparent adverse effects.

Term explanation
----------------

Bronchial artery chemical infusion employs direct injection of chemotherapeutics at high concentrations into local lesions of lung cancer, with the potential to reduce the tumor size and to relieve symptoms, with low toxicity and good repeatability.

Experiences and lessons
-----------------------

This case report suggests that the combination of oral icotinib hydrochloride and BAI chemotherapy is safe, well-tolerated and effective in Chinese patients suffering from advanced NSCLC with EGFR gene mutations.
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